NDC 47783-0644-01: TAKHZYRO lanadelumab-flyo 300 mg/2mL Injection, Solution
This is a package of TAKHZYRO lanadelumab-flyo 300 mg/2mL Injection, Solution from Takeda Pharmaceuticals America, Inc., no longer marketed (first marketed Aug 2018), no longer in the FDA NDC Directory. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 47783-644-01 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 47783 labeler · 644 product · 01 package
- Package marketed since
- Aug 24, 2018
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 4778364401 5
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 078791
- GCN: 45184
- GPI-14 (Medi-Span): 85842040202020
- HICL (First Databank): 045177
- AHFS class code: 24:48.08.00
- RxCUI (RxNorm): 2055645
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Plasma Kallikrein Inhibitor class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Lanadelumab-flyo injection is used to prevent swelling and painful attacks of hereditary angioedema (HAE; an inherited condition that causes episodes of swelling in the hands, feet, face, airway, or intestines) in adults and children 2 years of age or older. Lanadelumab-flyo is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes swelling and pain associated with HAE.
Read the full MedlinePlus article ↗- It helps prevent attacks of hereditary angioedema, or HAE, which causes sudden swelling. It is meant to be used regularly to lower the chance of attacks, not to treat one once it h...
- It is an injection under the skin, usually every 2 or 4 weeks depending on your age and how well controlled you are. Take the syringe out of the fridge 15 minutes ahead and inject...
- The most common is soreness, redness or bruising where you injected. Some people also get colds, headache, rash, dizziness, diarrhea or muscle aches. These are usually manageable,...
- Get medical help if you think you are having a serious allergic reaction after an injection. Stop using the medicine and let your doctor know. Also don’t use a syringe if the liqui...
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $13,424.97 | $67,124.87 / 5 ml |
| Medicare Part B allowsASP · J0593 | $88.216 / J0593 unit | — |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Billing & reimbursement
Where does this data come from?
- CMS ASP NDC-HCPCS crosswalk · refreshed Nov 22, 2026
- DMEPDAC NDC-HCPCS crosswalk
- openFDA NSDE billing units · refreshed Nov 7, 2026
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 47783-0644-01 You're viewing this Main listing | 1 VIAL, GLASS in 1 CARTON / 5 mL in 1 VIAL, GLASS | 2018-08-24 | — | Discontinued by firm |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Takhzyro 300 mg/2mLthis 47783-0644-01 | Takeda | 1 vial | — | — | Discontinued | — |
| Takhzyro 300 mg/2mL 47783-0646-01 | Takeda | 1 syringe | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Aug 23, 2030 |
Is there a biosimilar for TAKHZYRO 300 MG/2 ML VIAL?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Lanadelumab-flyo injection inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 2968PHW8QP
A weak organic acid derived from citrus fruits or made through fermentation. It works as a buffer to control pH, a preservative to extend shelf life, and a flavoring agent in medications.
-
UNII 4QD397987E
An amino acid used as a buffer and stabilizer in medications. It helps maintain the pH balance and protects the active drug from breaking down during storage and use.
-
UNII 6OZP39ZG8H
Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 94255I6E2T
Sodium phosphate dibasic dihydrate is a salt that helps control the acidity level of a medicine. It acts as a buffer and pH regulator to keep the medication stable and effective.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Takeda Pharmaceuticals America, Inc. labeler code 47783
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For subcutaneous use only. Recommended Dosage: Adult and pediatric patients 12 years of age and older: administer 300 mg every 2 weeks by the patient or caregiver. Dosing interval every 4 weeks may be considered in some patients.
( 2.1 ) Pediatric patients 6 years to less than 12 years of age: administer 150 mg every 2 weeks by a healthcare provider or caregiver. Dosing interval every 4 weeks may be considered in some patients. ( 2.2 ) Pediatric patients 2 years to less than 6 years of age: administer 150 mg every 4 weeks by a healthcare provider or caregiver.
( 2.2 ) See Full Prescribing Information for Preparation and Administration Instructions. ( 2.3 )
2.1Recommended Dosage for Adult and Pediatric Patients 12 Years of Age and Older The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg administered subcutaneously every 2 weeks (q2wks). A dosing interval of 300 mg every 4 weeks (q4wks) is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.
2.2Recommended Dosage for Pediatric Patients 2 Years to Less Than 12 Years of Age Pediatric Patients 6 Years to Less Than 12 Years of Age The recommended starting dosage in pediatric patients 6 years to less than 12 years of age is 150 mg administered subcutaneously every 2 weeks (q2wks). A dosing interval of 150 mg every 4 weeks (q4wks) may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months. Pediatric Patients 2 Years to Less Than 6 Years of Age The recommended dosage in pediatric patients 2 years to less than 6 years of age is 150 mg administered subcutaneously every 4 weeks (q4wks).
2.3Preparation and Administration Instructions TAKHZYRO is administered subcutaneously only. TAKHZYRO is intended for administration by a healthcare provider, patient or caregiver. The patient or caregiver should be trained in subcutaneous injection technique by a healthcare professional.
Adult and pediatric patients 12 years of age and older: TAKHZYRO may be administered by the patient or caregiver. Pediatric patients 2 years to less than 12 years of age: TAKHZYRO should be administered by a healthcare provider or caregiver. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Do not use TAKHZYRO if the solution appears discolored or contains visible particles. TAKHZYRO is a clear to slightly opalescent, colorless to slightly yellow solution. Administration Instructions for Single-Dose Prefilled Syringes Instruct patients and/or caregivers on proper use of the TAKHZYRO prefilled syringe and assess that they are well trained in subcutaneous injection technique prior to administration by patient and/or caregiver.
Avoid vigorous agitation of the prefilled syringe. Take the TAKHZYRO prefilled syringe out of the refrigerator 15 minutes before injecting to allow it to equilibrate to room temperature. Using aseptic technique, inject TAKHZYRO subcutaneously into the abdomen, thigh, or upper arm.
Discard any unused portion of drug remaining in the prefilled syringe. For detailed instructions on the preparation and administration of TAKHZYRO see Instructions for Use for either single-dose 1 mL prefilled syringe or single-dose 2 mL prefilled syringe.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Injection: Sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution available as follows: 150 mg/mL solution in a single-dose prefilled syringe 300 mg/2 mL (150 mg/mL) solution in a single-dose prefilled syringe Injection: 150 mg/mL solution in a single-dose prefilled syringe. ( 3 ) 300 mg/2 mL (150 mg/mL) solution in a single-dose prefilled syringe. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS None. None. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment. ( 5.1 )
5.1Hypersensitivity Reactions Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most common adverse reactions (≥10%) are injection site reactions, upper respiratory infections, headache, rash, dizziness, diarrhea, and myalgia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult and Pediatric Patients 12 Years of Age and Older The safety of TAKHZYRO is primarily based on a 26-week, randomized, double-blind, parallel-group and placebo-controlled study (Trial 1) in 125 patients with Type I or II HAE.
Eligible patients were also able to participate in an open-label extension study (Trial 2) up to 130 weeks. In Trial 1, a total of 84 patients with HAE aged 12 years and older received at least one dose of TAKHZYRO. Overall, 70% of patients were female and 90% of patients were Caucasian with a mean age of 41 years.
The proportion of patients who discontinued study drug prematurely due to adverse events was 1.2% for TAKHZYRO-treated patients and 4.9% for placebo-treated patients. No deaths occurred in the trial. The safety profile of TAKHZYRO was generally similar across all subgroups of patients, including analysis by age, sex, and geographic region.
Table 1 shows adverse reactions occurring in ≥10% of patients in any TAKHZYRO treatment group that also occurred at a higher rate than in the placebo treatment group in Trial 1. Table 1 Adverse Reactions Observed in ≥10% of Patients Treated with TAKHZYRO in Trial 1 Adverse Reaction Placebo (N=41) n (%) TAKHZYRO 150 mg q4wks (N=28) n (%) TAKHZYRO 300 mg q4wks (N=29) n (%) TAKHZYRO 300 mg q2wks (N=27) n (%) TAKHZYRO Total (N=84) n (%) N= number of patients; n =number of patients experiencing the event; q2wks = every 2 weeks; q4wks = every 4 weeks Injection site reactions Injection site reactions include: pain, erythema, bruising, hematoma, hemorrhage, pruritus, swelling, induration, paresthesia, reaction, warmth, edema and rash.
14 (34) 16 (57) 13 (45) 15 (56) 44 (52) Upper respiratory infection Includes upper respiratory infection, viral upper respiratory infection 13 (32) 3 (11) 9 (31) 12 (44) 24 (29) Headache Includes headache, tension headache, sinus headache 9 (22) 3 (11) 6 (21) 9 (33) 18 (21) Rash Includes rash, rash maculopapular, rash erythematous 2(5) 2 (7) 3 (10) 1 (4) 6 (7) Dizziness 0 1 (4) 3 (10) 1 (4) 5 (6) Diarrhea 2 (5) 3 (11) 0 1 (4) 4 (5) Myalgia 0 1 (4) 0 3 (11) 4 (5) Injection site reactions primarily consisted mainly of pain, erythema, and bruising at the injection site.
There was no meaningful difference in injection site reactions with self-administration. Less Common Adverse Reactions Other adverse reactions that occurred at a higher incidence in TAKHZYRO-treated patients compared to placebo include hypersensitivity (1% vs 0%), increased aspartate transaminase (2% vs 0%), and increased alanine transaminase (2% vs 0%). Safety data from the open-label extension study, consisting of 109 rollover patients from Trial 1 and 103 non-rollover HAE patients, is consistent with controlled safety data from Trial 1.
Laboratory Abnormalities Transaminase elevations During the placebo-controlled treatment period in Trial 1, the number of TAKHZYRO-treated patients with maximum transaminase (ALT or AST) levels >8, >5, or >3 times the upper limit of normal (ULN) was 1 (1.2%), 0 (0%), or 3 (3.6%) respectively, compared to 0 in the placebo-treated patients. These transaminase elevations were asymptomatic and transient. No patients had elevated total bilirubin >2× ULN.
One TAKHZYRO-treated patient permanently discontinued treatment due to elevated transaminases (4.1× ULN AST). None of the patients were reported to have serious adverse r… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS No dedicated drug interaction studies have been conducted [see Clinical Pharmacology (12.3) ]. No dedicated drug interaction studies have been conducted. ( 7 )
7.1Drug-Laboratory Test Interactions Coagulation tests TAKHZYRO can increase activated partial thromboplastin time (aPTT) due to an interaction of TAKHZYRO with the aPTT assay. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. Inhibition of plasma kallikrein by TAKHZYRO can increase aPTT in this assay.
In Trial 1, prolongation of aPTT (>1× ULN) was observed at one or more time points in 3, 9, and 11 patients treated with TAKHZYRO 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks), and 300 mg every 2 weeks (q2wks), respectively, compared to 5 placebo-treated patients. Only one patient in the 300 mg every 2 weeks (q2wks) treatment group experienced transient aPTT prolongation ≥1.5x ULN which was confounded by ongoing heparin therapy. None of the increases in aPTT in patients treated with TAKHZYRO were associated with abnormal bleeding adverse events.
There were no differences in INR values between treatment groups.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary There are no available data on TAKHZYRO use in pregnant women to inform any drug associated risks. Monoclonal antibodies such as lanadelumab-flyo are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. An enhanced pre- and postnatal development (ePPND) study conducted in pregnant monkeys at doses resulting in exposures of up to 33 times the exposure achieved (on an AUC basis) at the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In the ePPND study, pregnant cynomolgus monkeys were administered lanadelumab-flyo once weekly at subcutaneous doses resulting in up to 33 times the exposure at the MRHD (on an AUC basis with maternal subcutaneous doses up to 50 mg/kg/week) from gestation day 20, at the beginning of organogenesis, through to parturition.
There were no lanadelumab-flyo-related effects on maintenance of pregnancy or parturition. Maternal lanadelumab-flyo treatment had no effects on embryo-fetal development, survival, growth, or postnatal development of offspring through 3 months of age. Lanadelumab-flyo crossed the placenta in monkeys.
Offspring were exposed to lanadelumab-flyo at approximately 50% of the maternal plasma concentration out to postnatal day 21 (PND 21). Lanadelumab-flyo concentrations were approximately equivalent in maternal and offspring plasma at PND 90.
8.2Lactation Risk Summary There are no data on the presence of lanadelumab-flyo in human milk, its effects on the breastfed infant, or its effects on milk production. Lanadelumab-flyo was detected in the milk of lactating cynomolgus monkeys at approximately 0.2% of the maternal plasma concentration. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TAKHZYRO and any potential adverse effects on the breastfed infant from TAKHZYRO or from the underlying maternal condition.
Data Animal Data Available pharmacokinetic data in cynomolgus monkeys have shown excretion of lanadelumab-flyo in milk at approximately 0.2% of the maternal plasma level.
8.4Pediatric Use The safety and effectiveness of TAKHZYRO for prophylaxis to prevent attacks of hereditary angioedema (HAE) have been established in pediatric patients 2 years of age and older. Use of TAKHZYRO for this indication in patients 12 years of age and older was supported by a subgroup analysis by age of 10 patients aged 12 years to <18 years in Trial 1 (a randomized, double-blind, placebo-controlled parallel-group study in adult and pediatric patients 12 years of age and older with HAE). Results of the subgroup analysis by age were consistent with overall study results.
An additional 13 pediatric patients aged 12 years to <18 years were enrolled in the open-label extension study [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) and Clinical Studies (14) ]. Use of TAKHZYRO for this indication in patients 2 years to less than 12 years of age was supported by extrapolation of efficacy data from Trial 1, an adequate and well controlled study in adult and pediatric (12 years to less than 18 years of age) patients, with additional pharmacokinetic analyses showing similar drug exposures between adults (>18 years of age) and pediatric patients (2 years to less than 12 years of age), and safety and pharmacodynamic data from an open-label, multicenter study in pediatric patients with HAE aged 2 years to less than 12 years that enrolled 21 patients (4 patients were aged 2 years to less than 6 years and 17 patients were 6 to less… [Excerpted — this section continues on DailyMed.]
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no available data on TAKHZYRO use in pregnant women to inform any drug associated risks. Monoclonal antibodies such as lanadelumab-flyo are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. An enhanced pre- and postnatal development (ePPND) study conducted in pregnant monkeys at doses resulting in exposures of up to 33 times the exposure achieved (on an AUC basis) at the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In the ePPND study, pregnant cynomolgus monkeys were administered lanadelumab-flyo once weekly at subcutaneous doses resulting in up to 33 times the exposure at the MRHD (on an AUC basis with maternal subcutaneous doses up to 50 mg/kg/week) from gestation day 20, at the beginning of organogenesis, through to parturition.
There were no lanadelumab-flyo-related effects on maintenance of pregnancy or parturition. Maternal lanadelumab-flyo treatment had no effects on embryo-fetal development, survival, growth, or postnatal development of offspring through 3 months of age. Lanadelumab-flyo crossed the placenta in monkeys.
Offspring were exposed to lanadelumab-flyo at approximately 50% of the maternal plasma concentration out to postnatal day 21 (PND 21). Lanadelumab-flyo concentrations were approximately equivalent in maternal and offspring plasma at PND 90.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of TAKHZYRO for prophylaxis to prevent attacks of hereditary angioedema (HAE) have been established in pediatric patients 2 years of age and older. Use of TAKHZYRO for this indication in patients 12 years of age and older was supported by a subgroup analysis by age of 10 patients aged 12 years to <18 years in Trial 1 (a randomized, double-blind, placebo-controlled parallel-group study in adult and pediatric patients 12 years of age and older with HAE). Results of the subgroup analysis by age were consistent with overall study results.
An additional 13 pediatric patients aged 12 years to <18 years were enrolled in the open-label extension study [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) and Clinical Studies (14) ]. Use of TAKHZYRO for this indication in patients 2 years to less than 12 years of age was supported by extrapolation of efficacy data from Trial 1, an adequate and well controlled study in adult and pediatric (12 years to less than 18 years of age) patients, with additional pharmacokinetic analyses showing similar drug exposures between adults (>18 years of age) and pediatric patients (2 years to less than 12 years of age), and safety and pharmacodynamic data from an open-label, multicenter study in pediatric patients with HAE aged 2 years to less than 12 years that enrolled 21 patients (4 patients were aged 2 years to less than 6 years and 17 patients were 6 to less than 12 years of age) [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] .
The pharmacodynamic response observed in this trial for pediatric patients 2 years to less than 12 years of age was similar to that seen in adult and pediatric patients 12 years of age and older [see Clinical Pharmacology (12.2) ] . The safety and effectiveness of TAKHZYRO in pediatric patients less than 2 years of age have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use The safety and effectiveness of TAKHZYRO were evaluated in a subgroup of patients (N=5) aged ≥65 years in Trial 1. Results of the subgroup analysis by age were consistent with overall study results [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) and Clinical Studies (14) ] .
🆘 Overdosage ▾
10 OVERDOSAGE There is no clinical experience with overdosage of TAKHZYRO.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Lanadelumab-flyo is a fully human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks.
Lanadelumab-flyo decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE.
12.2Pharmacodynamics In adult and pediatric (12 years to less than 18 years of age) patients, concentration-dependent inhibition of plasma kallikrein, measured as reduction of cHMWK levels, was demonstrated after subcutaneous administration of TAKHZYRO 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks) or 300 mg every 2 weeks (q2wks) in patients with HAE. For pediatric patients 2 years to less than 6 years of age (150 mg every 4 weeks (q4wks)) and 6 years to less than 12 years (150 mg every 2 weeks (q2wks)), the observed mean percent change from baseline cHMWK levels was similar to that observed in adult and pediatric (12 years to less than 18 years of age) patients (300 mg every 2 weeks (q2wks) or 300 mg every 4 weeks (q4wks)).
Cardiac Electrophysiology TAKHZYRO did not prolong the QT/QTc interval.
12.3Pharmacokinetics Following subcutaneous administration, the pharmacokinetics of lanadelumab-flyo was approximately dose-proportional in the therapeutic dose range in patients with HAE (Table 2). The pharmacokinetic properties and exposure (steady state) of lanadelumab-flyo in HAE patients, following subcutaneous administration of 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks) and 300 mg every 2 weeks (q2wks), are provided in Table 2 . Following subcutaneous administration of TAKHZYRO, peak plasma concentrations are reached within 5 days, and terminal elimination half-life is ~ 2 weeks.
The anticipated time to reach steady state concentration was approximately 70 days. At steady-state, the mean accumulation ratio is approximately 1.44, 1.42, and 2.43 for dosing regimen of 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks) and 300 mg every 2 weeks (q2wks), respectively. Table 2 Mean (SD) Pharmacokinetic Parameters of Lanadelumab-flyo Following Subcutaneous Administration (Trial 1) Pharmacokinetic Parameters Lanadelumab-flyo 150 mg q4wks (N=28) Lanadelumab-flyo 300 mg q4wks (N=29) Lanadelumab-flyo 300 mg q2wks (N=27) CL/F: apparent clearance; Vc/F: apparent volume of distribution; AUC tau,ss : area under the curve over the dosing interval at steady-state; C max,ss : maximum concentration at steady-state; C min,ss : minimum concentration at steady state; t max : time to maximum concentration; t 1/2 terminal elimination half-life.
CL/F (L/day) 0.667 (0.162) 0.742 (0.239) 0.809 (0.370) Vc/F (L) 14.1 (2.93) 14.9 (4.45) 16.6 (4.79) AUC tau,ss (µg*day/mL) 233 (56.6) 441(137) 408 (138) C max,ss (µg/mL) 12.0 (3.01) 23.3 (7.94) 34.4 (11.2) C min,ss (µg/mL) 4.81 (1.40) 8.77 (2.80) 25.4 (9.18) t max (day) 5.17 (1.09) 5.17 (1.12) 4.11 (0.377) t 1/2 (day) 14.9 (2.00) 14.2 (1.89) 15.0 (2.48) Specific Populations Population pharmacokinetic analyses showed that age, gender and race did not meaningfully influence the pharmacokinetics of lanadelumab-flyo after correcting for body weight.
Body weight was identified as an important covariate describing the variability of clearance and volume of distribution, resulting in higher exposure (AUC and C max ) in lighter patients. However, this difference is not considered to be clinically relevant and no dose adjustments are recommended for any of these demographics. Pediatric Population Based on… [Excerpted — this section continues on DailyMed.]
🧬 Mechanism of Action ▾
12.1Mechanism of Action Lanadelumab-flyo is a fully human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks.
Lanadelumab-flyo decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied TAKHZYRO (lanadelumab-flyo) injection is a ready-to-use, clear to slightly opalescent, colorless to slightly yellow solution supplied in the following presentations. Single-dose prefilled syringe Supplied in a carton containing one single-dose prefilled syringe with a bromobutyl rubber stopper, 27-gauge, ½-inch staked needle and rigid needle cap. NDC 47783-645-01: 150 mg/mL prefilled syringe NDC 47783-646-01: 300 mg/2 mL (150 mg/mL) prefilled syringe Storage and Handling Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C).
Do not freeze. Do not shake. Keep the prefilled syringe in the original carton to protect from light.
📦 Storage and Handling ▾
Storage and Handling Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C). Do not freeze. Do not shake. Keep the prefilled syringe in the original carton to protect from light.
📋 Description ▾
11 DESCRIPTION Lanadelumab-flyo, a plasma kallikrein inhibitor, is a non-plasma derived, recombinant, fully human, monoclonal antibody (IgG1/κ-light chain) produced in Chinese Hamster Ovary (CHO) cells. Based on the amino acid sequence, the molecular weight of the non-glycosylated lanadelumab-flyo is 146 kDa. The calculated molecular mass of the fully reduced light chain is 23 kDa.
The calculated molecular mass of the fully reduced and non-glycosylated heavy chain is 49 kDa. TAKHZYRO (lanadelumab-flyo) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use. Each mL of ready-to-use TAKHZYRO solution contains 150 mg of lanadelumab-flyo, citric acid monohydrate (4.1 mg), L-histidine (7.8 mg), polysorbate 80 (0.1 mg), sodium chloride (5.3 mg), sodium phosphate dibasic dihydrate (5.3 mg), and Water for Injection, USP.
The solution has a pH of approximately 6.0.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Hypersensitivity Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions (5.1) ] . Self-Administration: Ensure that the patient or caregiver receives clear instructions and training on subcutaneous administration and has demonstrated the ability to perform a subcutaneous injection.
Instruct patients or caregivers in the technique of proper syringe and needle disposal, and advise them not to reuse these items. Instruct patients or caregivers to dispose needles and syringes in a puncture-resistant container.
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics Following subcutaneous administration, the pharmacokinetics of lanadelumab-flyo was approximately dose-proportional in the therapeutic dose range in patients with HAE (Table 2). The pharmacokinetic properties and exposure (steady state) of lanadelumab-flyo in HAE patients, following subcutaneous administration of 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks) and 300 mg every 2 weeks (q2wks), are provided in Table 2 . Following subcutaneous administration of TAKHZYRO, peak plasma concentrations are reached within 5 days, and terminal elimination half-life is ~ 2 weeks.
The anticipated time to reach steady state concentration was approximately 70 days. At steady-state, the mean accumulation ratio is approximately 1.44, 1.42, and 2.43 for dosing regimen of 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks) and 300 mg every 2 weeks (q2wks), respectively. Table 2 Mean (SD) Pharmacokinetic Parameters of Lanadelumab-flyo Following Subcutaneous Administration (Trial 1) Pharmacokinetic Parameters Lanadelumab-flyo 150 mg q4wks (N=28) Lanadelumab-flyo 300 mg q4wks (N=29) Lanadelumab-flyo 300 mg q2wks (N=27) CL/F: apparent clearance; Vc/F: apparent volume of distribution; AUC tau,ss : area under the curve over the dosing interval at steady-state; C max,ss : maximum concentration at steady-state; C min,ss : minimum concentration at steady state; t max : time to maximum concentration; t 1/2 terminal elimination half-life.
CL/F (L/day) 0.667 (0.162) 0.742 (0.239) 0.809 (0.370) Vc/F (L) 14.1 (2.93) 14.9 (4.45) 16.6 (4.79) AUC tau,ss (µg*day/mL) 233 (56.6) 441(137) 408 (138) C max,ss (µg/mL) 12.0 (3.01) 23.3 (7.94) 34.4 (11.2) C min,ss (µg/mL) 4.81 (1.40) 8.77 (2.80) 25.4 (9.18) t max (day) 5.17 (1.09) 5.17 (1.12) 4.11 (0.377) t 1/2 (day) 14.9 (2.00) 14.2 (1.89) 15.0 (2.48) Specific Populations Population pharmacokinetic analyses showed that age, gender and race did not meaningfully influence the pharmacokinetics of lanadelumab-flyo after correcting for body weight.
Body weight was identified as an important covariate describing the variability of clearance and volume of distribution, resulting in higher exposure (AUC and C max ) in lighter patients. However, this difference is not considered to be clinically relevant and no dose adjustments are recommended for any of these demographics. Pediatric Population Based on population pharmacokinetics (PK) analyses, the geometric mean lanadelumab-flyo average concentration at steady state (C ave ) was approximately 25% higher following subcutaneous administration of TAKHZYRO 300 mg every 2 weeks (q2wks) in pediatric patients 12 years to less than 18 years of age than the mean C ave in adult patients under the same dosing regimen, due to lower body weight in pediatric patients.
Lanadelumab-flyo exposures in pediatric patients 2 years to less than 12 years of age receiving TAKHZYRO 150 mg every 2 weeks (q2wks) or every 4 weeks (q4wks) are comparable to those in adult patients receiving TAKHZYRO 300 mg every 2 weeks (q2wks). The geometric mean lanadelumab-flyo C ave was approximately 7% higher following subcutaneous administration of TAKHZYRO 150 mg every 2 weeks (q2wks) in pediatric patients 6 years to less than 12 years of age compared to the mean C ave in adult patients receiving 300 mg every 2 weeks (q2wks).
The mean lanadelumab-flyo C ave was approximately 14% lower following subcutaneous administration of TAKHZYRO 150 mg every 4 weeks (q4wks) in pediatric patients 2 years to less than 6 years of age compared to the mean C ave in adult patients receiving 300 mg every 2 weeks (q2wks). Renal Impairment No dedicated studies have been conducted to evaluate the PK of lanadelumab-flyo in renal impairment patients. Based on population pharmacokinetic analysis, renal impairment (estimated GFR: 60 to 89 mL/min/1.73m 2 , [mild, N=98] and 30 to 59 mL/min/1.73m 2 , [moderate, N=9]) had no effect on the clearance or volume of distribution of lanadelumab-flyo.
Concomita… [Excerpted — this section continues on DailyMed.]
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics In adult and pediatric (12 years to less than 18 years of age) patients, concentration-dependent inhibition of plasma kallikrein, measured as reduction of cHMWK levels, was demonstrated after subcutaneous administration of TAKHZYRO 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks) or 300 mg every 2 weeks (q2wks) in patients with HAE. For pediatric patients 2 years to less than 6 years of age (150 mg every 4 weeks (q4wks)) and 6 years to less than 12 years (150 mg every 2 weeks (q2wks)), the observed mean percent change from baseline cHMWK levels was similar to that observed in adult and pediatric (12 years to less than 18 years of age) patients (300 mg every 2 weeks (q2wks) or 300 mg every 4 weeks (q4wks)).
Cardiac Electrophysiology TAKHZYRO did not prolong the QT/QTc interval.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Trial 1 (NCT02586805) The efficacy of TAKHZYRO for the prevention of angioedema attacks in patients 12 years of age and older with Type I or II HAE was demonstrated in a multicenter, randomized, double-blind, placebo-controlled parallel-group study (Trial 1). The study included 125 adult and pediatric patients (12 years of age and older) with Type I or II HAE who experienced at least one investigator-confirmed attack per 4 weeks during the run-in period. Patients were randomized into 1 of 4 parallel treatment arms, stratified by baseline attack rate, in a 3:2:2:2 ratio (placebo, lanadelumab-flyo 150 mg every 4 weeks (q4wks), lanadelumab-flyo 300 mg every 4 weeks (q4wks), or lanadelumab-flyo 300 mg every 2 weeks (q2wks) by subcutaneous injection) for the 26-week treatment period.
Patients ≥18 years of age were required to discontinue other prophylactic HAE medications prior to entering the study; however, all patients were allowed to use rescue medications for treatment of breakthrough HAE attacks. Overall, 90% of patients had Type I HAE. A history of laryngeal angioedema attacks was reported in 65% of patients and 56% were on prior long-term prophylaxis.
During the study run-in period, attack rates of ≥3 attacks/month were observed in 52% of patients overall. All TAKHZYRO treatment arms produced clinically meaningful and statistically significant reductions in the mean HAE attack rate compared to placebo across all primary and secondary endpoints in the Intent-to-Treat population (ITT) as shown in Table 3 . Table 3 Results of Primary and Secondary Efficacy Measures-ITT Population Endpoint Statistics Placebo (N=41) TAKHZYRO 150 mg q4wks (N=28) TAKHZYRO 300 mg q4wks (N=29) TAKHZYRO 300 mg q2wks (N=27) CI=confidence interval; LS=least squares.
Note: Results are from a Poisson regression model accounting for over dispersion with fixed effects for treatment group (categorical) and normalized baseline attack rate (continuous), and the logarithm of time in days each patient was observed during the treatment period as an offset variable in the model. Number of HAE Attacks from Day 0 to 182 Primary efficacy endpoint. LS Mean (95% CI) monthly attack rate Model-based treatment period HAE attack rate (attacks/4 weeks).
1.97(1.64, 2.36) 0.48 (0.31, 0.73) 0.53 (0.36, 0.77) 0.26 (0.14, 0.46) % Reduction relative to placebo (95% CI) Calculated as the ratio of the model-based treatment period HAE attack rates (lanadelumab/placebo) minus 1 multiplied by 100. - 76 (61, 85) 73 (59, 82) 87 (76, 93) Adjusted p-values Adjusted p-values for multiple testing. - <0.001 <0.001 <0.001 Number of HAE Attacks Requiring Acute Treatment from Day 0 to 182 LS Mean (95% CI) monthly attack rate 1.64 (1.34, 2.00) 0.31 (0.18, 0.53) 0.42 (0.28, 0.65) 0.21 (0.11, 0.40) % Reduction relative to placebo (95% CI) - 81 (66, 89) 74 (59, 84) 87 (75, 93) Adjusted p-values - <0.001 <0.001 <0.001 Number of Moderate or Severe HAE Attacks from Day 0 to 182 LS Mean (95% CI) monthly attack rate 1.22 (0.97, 1.52) 0.36 (0.22, 0.58) 0.32 (0.20, 0.53) 0.20 (0.11, 0.39) % Reduction relative to placebo (95% CI) - 70 (50, 83) 73 (54, 84) 83 (67, 92) Adjusted p-values - <0.001 <0.001 <0.001 The mean reduction in HAE attack rate was consistently higher across the TAKHZYRO treatment arms compared to placebo regardless of the baseline history of prior long-term prophylaxis, laryngeal attacks, or attack rate during the run-in period.
Additional pre-defined exploratory endpoints included the percentage of patients who were attack free for the entire 26-week treatment period and the percentage of patients achieving threshold (≥50%, ≥70%, ≥90%) reductions in HAE attack rates compared to run-in during the 26-week treatment period. A ≥50% reduction in HAE attack rate was observed in 100% of patients on 300 mg every 2 weeks (q2wks) or every 4 weeks (q4wks) and 89% on 150 mg every 4 weeks (q4wks) compared to 32% of placebo patients. A ≥70% reduction in HAE attack rates was obser… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to evaluate the carcinogenic potential of lanadelumab-flyo. Published literature supports bradykinin, which is elevated in HAE, as a pro-tumorigenic molecule. However, the malignancy risk in humans from an antibody that inhibits plasma kallikrein activity, such as lanadelumab-flyo, which lowers bradykinin levels, is currently unknown.
Male and female fertility were unaffected based upon no observed adverse histopathological findings in the reproductive organs from sexually mature cynomolgus monkeys that received lanadelumab-flyo for 13 weeks at subcutaneous doses up to 50 mg/kg/week (resulting in approximately 22 times the exposure at the MRHD on an AUC basis).
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to evaluate the carcinogenic potential of lanadelumab-flyo. Published literature supports bradykinin, which is elevated in HAE, as a pro-tumorigenic molecule. However, the malignancy risk in humans from an antibody that inhibits plasma kallikrein activity, such as lanadelumab-flyo, which lowers bradykinin levels, is currently unknown.
Male and female fertility were unaffected based upon no observed adverse histopathological findings in the reproductive organs from sexually mature cynomolgus monkeys that received lanadelumab-flyo for 13 weeks at subcutaneous doses up to 50 mg/kg/week (resulting in approximately 22 times the exposure at the MRHD on an AUC basis).
📄 Patient Package Insert ▾
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 8/2026 PATIENT INFORMATION TAKHZYRO ® (tak-ZYE-roe) (lanadelumab-flyo) injection, for subcutaneous use Read this Patient Information before you start using TAKHZYRO and each time you get a refill.
There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. What is TAKHZYRO?
TAKHZYRO is a prescription medicine used to prevent attacks of Hereditary Angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age. Before you use TAKHZYRO, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or planning to become pregnant.
It is not known if TAKHZYRO can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if TAKHZYRO passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby while using TAKHZYRO.
Tell your healthcare provider about all the medicines you take , including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. How should I use TAKHZYRO? See the detailed Instructions for Use that comes with this patient information leaflet about the right way to prepare and inject TAKHZYRO.
Use TAKHZYRO exactly as your healthcare provider tells you to use it. TAKHZYRO is given as an injection under your skin (subcutaneous) by you or a caregiver. Your healthcare provider should show you or your caregiver how to prepare and inject your dose of TAKHZYRO before you inject yourself for the first time.
Do not try to inject TAKHZYRO unless you have been trained by your healthcare provider. Self-injection is not recommended in children (2 years to less than 12 years). What are the possible side effects of TAKHZYRO?
TAKHZYRO may cause serious side effects, including allergic reactions. Allergic reactions may happen with TAKHZYRO. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing difficulty breathing chest tightness fast heartbeat faintness rash hives The most common side effects of TAKHZYRO are: injection site reactions (pain, redness, and bruising) upper respiratory infections headache rash dizziness diarrhea muscle aches Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of TAKHZYRO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.
Do not use TAKHZYRO for a condition for which it is not prescribed. Do not give TAKHZYRO to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about TAKHZYRO that is written for health professionals. What are the ingredients in TAKHZYRO? Active ingredient: lanadelumab Inactive ingredients: citric acid monohydrate, L-histidine, sodium chloride, sodium phosphate dibasic dihydrate and water for injection.
Manufactured by: Takeda Pharmaceuticals U.S.A., Inc. Cambridge, MA 02142 U.S. License No.
1898 TAKHZYRO is a registered trademark of Dyax Corp. Takeda and are registered trademarks of Takeda Pharmaceutical Company Limited. ©2026 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
For more information, visit www.TAKHZYRO.com or call 1-877-TAKEDA-7 (1-877-825-3327).
📖 Instructions for Use ▾
INSTRUCTIONS FOR USE TAKHZYRO ® (tak-ZYE-roe) (lanadelumab-flyo) injection, for subcutaneous use single-dose 1 mL prefilled syringe This Instructions for Use contains information on how to inject TAKHZYRO. Please make sure to read, understand, and follow the Instructions for Use before injecting TAKHZYRO. A healthcare provider should show you how to prepare and inject TAKHZYRO properly before you use it for the first time.
Contact your healthcare provider if you have any questions. Important information: TAKHZYRO is a ready-to-use prefilled syringe ( Figure A ) for injection under the skin (subcutaneous) to be given to children by their healthcare provider or caregiver. Self-injection is not recommended in children (2 years to less than 12 years of age).
Each TAKHZYRO prefilled syringe contains one 150 mg/mL dose. The TAKHZYRO prefilled syringe is for single use only. Figure A: TAKHZYRO prefilled syringe Storing TAKHZYRO: Store the TAKHZYRO prefilled syringe in the refrigerator between 36°F to 46°F (2°C to 8°C).
Do not freeze. Store the TAKHZYRO prefilled syringe in the original carton to protect it from light. Throw away (discard) the TAKHZYRO prefilled syringe if it has been kept out of the refrigerator, frozen, or not kept in the original carton protected from light.
Do not shake the TAKHZYRO prefilled syringe. Keep the TAKHZYRO prefilled syringe and all medicines out of the reach of children. Step 1: Prepare for your injection a.
Gather an alcohol swab, cotton ball or gauze pad, adhesive bandage, and sharps disposal container ( Figure B ) and place the supplies on a clean, flat, surface in a well-lit area. These supplies are not included in the TAKHZYRO carton. Figure B: Supplies b.
Remove the TAKHZYRO prefilled syringe carton from the refrigerator 15 minutes before injecting. Do not use if the seal on the carton is open or broken. Your medicine is sensitive to warm temperatures .
Do not use heat sources such as a microwave or hot water to warm your TAKHZYRO prefilled syringe. c. Open the carton. Hold the syringe barrel and remove the TAKHZYRO prefilled syringe from the tray ( Figure C ).
Do not remove the needle cap until you are ready to inject. Do not touch or push the plunger rod until you are ready to inject. Figure C: Remove prefilled syringe d.
Wash your hands with soap and water ( Figure D ). Dry your hands completely. Do not touch any surface or body part after washing your hands before the injection.
Figure D: Wash hands e. Check the expiration date (EXP) on the syringe barrel ( Figure E ). Do not use the TAKHZYRO prefilled syringe if the expiration date has passed.
If the TAKHZYRO prefilled syringe is expired throw it away (discard) in a sharps disposal container and contact your healthcare provider. Figure E: Location of expiration date f. Inspect the TAKHZYRO prefilled syringe for any damage.
The medicine inside the syringe barrel should be colorless to slightly yellow ( Figure F ). Do not use the TAKHZYRO prefilled syringe if the syringe is damaged or cracked. Do not use the TAKHZYRO prefilled syringe if the medicine is discolored, cloudy, or has flakes or particles in it.
You may see air bubbles in the TAKHZYRO prefilled syringe. This is normal and will not affect your dose. If you cannot use the prefilled syringe, contact your healthcare provider.
Figure F: Inspect the prefilled syringe Step 2: Select and prepare injection site a. TAKHZYRO should be injected by a healthcare provider or caregiver into the following sites only ( Figure G ): stomach area (abdomen) thighs upper arms Do not inject into an area where the skin is irritated, red, bruised, or infected. The area you choose for injection should be at least 2 inches away from any scars or belly button (navel).
Important: Change (rotate) injection sites to keep skin healthy. Each new injection should be given at least 1 inch from the last site you used. Figure G: Injection sites b.
Clean the injection site with an alcohol swab and allow it to dry complet… [Excerpted — this section continues on DailyMed.]
📄 Recent Major Changes ▾
Dosage and Administration, Administration Instructions for Single-Dose Vial ( 2.3 ) Removed 8/2026
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 2 mL Syringe Carton NDC 47783-646-01 PREFILLED SYRINGE TAKHZYRO ® (lanadelumab-flyo) injection 300 mg/2 mL (150 mg/mL) 1 single-dose prefilled syringe. For Subcutaneous use only. Must be refrigerated, store at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. Do not shake. Keep out of reach of children. 2 mL Single-dose syringe Rx Only PRINCIPAL DISPLAY PANEL - 2 mL Syringe Carton
PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton Rx Only NDC 47783-644-01 TAKHZYRO ® (lanadelumab-flyo) injection 300 mg/2 mL (150 mg/mL) Single-dose Vial, for Subcutaneous use only. 2 mL 1 single-dose vial. Takeda PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton
PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Label NDC 47783-645-01 TAKHZYRO ® (lanadelumab-flyo) injection 150 mg/mL For Subcutaneous use only. Single-dose prefilled syringe Store refrigerated at 36°F to 46°F (2°C to 8°C). Takeda Pharmaceuticals U.S.A., Inc. | U.S. License No. 1898 LOT EXP Rx Only 0757712 PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Label
PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Carton NDC 47783-645-01 PREFILLED SYRINGE TAKHZYRO ® (lanadelumab-flyo) injection 150 mg/mL Attention: For pediatric use (2 to less than 12 years) For Subcutaneous use only. 1 single-dose prefilled syringe. Must be refrigerated, store at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.
Do not freeze. Do not shake. Keep out of reach of children.
1 mL Single-dose syringe Rx Only PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Carton
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | ✓ Available |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |